Key Highlights

  • ARKQ ETF offloaded 50,312 Rocket Lab shares valued at approximately $4 million on April 27
  • The transaction represents ARK’s second Rocket Lab reduction within days, following Friday’s 113,000+ share sale
  • ARK accumulated 263,848 Intellia Therapeutics shares totaling approximately $3.6 million through ARKK and ARKG funds
  • Iridium Communications saw 13,806 shares sold by ARK, representing roughly $538,000
  • Rocket Lab stock advanced 3.28% Monday, finishing at $82.29 amid the selloff

Cathie Wood’s investment firm ARK Invest executed multiple portfolio adjustments Monday, April 27, 2026, based on the company’s publicly filed fund transactions.

The primary transaction involved divesting 50,312 shares of Rocket Lab via the ARKQ ETF, representing approximately $4.01 million in value. This action followed ARK’s Friday disposal of more than 113,000 shares of the aerospace firm.


RKLB Stock Card
Rocket Lab USA, Inc., RKLB

The back-to-back transactions indicate ARK is systematically reducing its stake in the space technology enterprise.

The notable aspect of these trades involves the market performance of Rocket Lab’s stock, which climbed 3.28% Monday to settle at $82.29. ARK chose to liquidate shares during a rally rather than during a decline.

The timing appears strategic, positioned ahead of Rocket Lab’s Q1 2026 earnings announcement slated for May 7, 2026.

Financial analysts anticipate Rocket Lab will deliver quarterly revenues of $189.65 million, representing a 55% increase compared to the prior year period. Projections also indicate a narrowed loss of $0.07 per share, showing improvement from the $0.12 per-share deficit recorded in last year’s corresponding quarter.

ARK Increases Intellia Therapeutics Stake

Concurrently with reducing Rocket Lab exposure, ARK expanded its holdings in Intellia Therapeutics. The investment firm acquired 263,848 shares distributed between its ARKK and ARKG ETFs, valued at approximately $3.6 million.

Intellia operates in the gene-editing sector, and shares declined 4.33% during Monday’s session. ARK leveraged the price decline to increase its position.

This behavior aligns with ARK’s established strategy of expanding holdings during temporary price decreases in businesses the firm considers promising long-term opportunities.

ARK simultaneously divested 13,806 shares of Iridium Communications via its ARKX ETF, totaling around $538,000. This represents an ongoing reduction pattern — ARK disposed of 33,315 Iridium shares on the prior Friday and 81,422 shares the Monday preceding that transaction.

Wall Street Perspective on Rocket Lab

While ARK reduced its holdings, at least one equity analyst maintains an optimistic outlook on Rocket Lab.

Stifel analyst Erik Rasmussen elevated his price objective for the company to $105 from $90 while maintaining a Buy recommendation. His rationale included consistent revenue expansion, a robust contract pipeline, and the anticipated Neutron rocket debut scheduled for later this year.

Data from TipRanks indicates Rocket Lab carries a Moderate Buy consensus recommendation, comprising nine Buy ratings and four Hold ratings issued during the previous three months.

The consensus analyst price target stands at $89.00, suggesting approximately 8% appreciation potential from present valuation levels.

ARK’s upcoming daily transaction report will reveal whether the firm continued trimming its Rocket Lab allocation on Tuesday.